Overall survival at 5 years of follow-up from a phase 3 trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

Paolo A. Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, Caroline Robert, Vanna Chiarion-Sileni, Ana Arance, Celeste Lebbe, Inge Marie Svane, Catriona McNeil, Piotr Rutkowski, Carmen Loquai, Laurent Mortier, Omid Hamid, Lars Bastholt, Brigitte Dreno, Dirk Schadendorf, Claus Garbe, Marta Nyakas, Jean-Jacques Grob, Luc ThomasGabriella Liszkay, Michael Smylie, Simsek Burcin, Fareeda Hosein, Michele Maio

Research output: Contribution to journalConference abstract in journalResearch

Original languageEnglish
Article numberO23
JournalJournal of Translational Medicine
Volume17
Issue number1
Number of pages1
ISSN1479-5876
Publication statusPublished - 15. Jan 2019
EventIMMUNOTHERAPY BRIDGE 2018 - Naples, Italy
Duration: 28. Nov 201829. Nov 2018

Conference

ConferenceIMMUNOTHERAPY BRIDGE 2018
Country/TerritoryItaly
CityNaples
Period28/11/201829/11/2018

Cite this